NO873699D0 - Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser. - Google Patents

Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.

Info

Publication number
NO873699D0
NO873699D0 NO873699A NO873699A NO873699D0 NO 873699 D0 NO873699 D0 NO 873699D0 NO 873699 A NO873699 A NO 873699A NO 873699 A NO873699 A NO 873699A NO 873699 D0 NO873699 D0 NO 873699D0
Authority
NO
Norway
Prior art keywords
diagnosis
articles
dimension
treatment
autoimmune diseases
Prior art date
Application number
NO873699A
Other languages
English (en)
Other versions
NO873699L (no
Inventor
Willem Van Eden
Jelle Egbertus Rudolfus Thole
Johannes Dirk Anthonie Embden
Ruurd Van Der Zee
Irun Robert Cohen
Original Assignee
Nl Mini Welzijn Gesund Cultur
Univ Utrecht
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL8602270A external-priority patent/NL8602270A/nl
Application filed by Nl Mini Welzijn Gesund Cultur, Univ Utrecht, Yeda Res & Dev filed Critical Nl Mini Welzijn Gesund Cultur
Publication of NO873699D0 publication Critical patent/NO873699D0/no
Publication of NO873699L publication Critical patent/NO873699L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO873699A 1986-09-09 1987-09-04 Polypeptid som er egnet til dempning, behandling og diagnostisering av autoimmune lidelser saasom leddbetennelser. NO873699L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8602270A NL8602270A (nl) 1986-09-09 1986-09-09 Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8701163A NL8701163A (nl) 1986-09-09 1987-05-14 Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.

Publications (2)

Publication Number Publication Date
NO873699D0 true NO873699D0 (no) 1987-09-04
NO873699L NO873699L (no) 1988-03-10

Family

ID=26646154

Family Applications (1)

Application Number Title Priority Date Filing Date
NO873699A NO873699L (no) 1986-09-09 1987-09-04 Polypeptid som er egnet til dempning, behandling og diagnostisering av autoimmune lidelser saasom leddbetennelser.

Country Status (9)

Country Link
EP (1) EP0262710B1 (no)
JP (1) JP2505213B2 (no)
AU (1) AU601765B2 (no)
CA (1) CA1315225C (no)
DE (1) DE3781078T2 (no)
DK (1) DK467487A (no)
IL (1) IL83817A (no)
NL (1) NL8701163A (no)
NO (1) NO873699L (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4976958A (en) * 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US4952395A (en) * 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
ATE78407T1 (de) * 1988-10-21 1992-08-15 Akzo Nv Immunotoxine zur behandlung bzw. prophylaxe von autoimmunkrankheiten.
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5578303A (en) * 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5780034A (en) * 1989-03-14 1998-07-14 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
WO1994002509A1 (en) * 1992-07-15 1994-02-03 Rijksuniversiteit Leiden Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
EP1221488A1 (en) 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1995025744A1 (en) * 1994-03-21 1995-09-28 Rijksuniversiteit Utrecht Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
ES2191929T3 (es) 1997-08-05 2003-09-16 Stressgen Biotechnologies Corp Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas.
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのTh1様応答の誘導
DE60042704D1 (de) 2000-01-14 2009-09-17 Whitehead Biomedical Inst Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
EP2157101B1 (en) 2002-01-31 2014-09-24 Andromeda Bio Tech Ltd. HSP peptides and analogs for modulation of immune responses via antigen presenting cells
AU2003230181A1 (en) 2002-05-21 2003-12-02 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
CU23504A1 (es) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
EP1858548B1 (en) 2005-03-14 2012-06-20 Yeda Research And Development Co., Ltd. Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria

Also Published As

Publication number Publication date
DK467487A (da) 1988-03-10
DE3781078D1 (de) 1992-09-17
JP2505213B2 (ja) 1996-06-05
NL8701163A (nl) 1988-04-05
AU601765B2 (en) 1990-09-20
DE3781078T2 (de) 1992-12-24
NO873699L (no) 1988-03-10
EP0262710A1 (en) 1988-04-06
JPS63126895A (ja) 1988-05-30
IL83817A0 (en) 1988-02-29
CA1315225C (en) 1993-03-30
IL83817A (en) 1993-01-31
EP0262710B1 (en) 1992-08-12
DK467487D0 (da) 1987-09-08
AU7800087A (en) 1988-03-17

Similar Documents

Publication Publication Date Title
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
NO884795D0 (no) Rekombinant, humant immunoglobulin og fremgangsmaate for fremstilling av dette.
NO875378L (no) Fremgangsmaate for fremstilling av granulocyttstimulerendefaktor (polypeptidderivater).
NO872966L (no) Fremgangsmaate for fremstilling av granulocyttstimulerende preparater.
NO874530D0 (no) Fremgangsmaate for fremstilling av nor-statin- eller nor-cyklostatin-polypeptider.
NO880268D0 (no) Fremgangsmaate for fremstilling av anti-koagulerende peptider.
NO154905C (no) Fremgangsmaate for fremstilling av preparater for behandling av melanomer.
NO872376D0 (no) Eksoterm, ledende pasta og anvendelse av denne.
NO871025L (no) Polypeptid, dna og fremgangsmaate for fremstilling derav.
DE3882593T2 (de) Polypeptid und dessen Herstellung.
DE3777861D1 (de) Behandlung von gasen.
DE3684755D1 (de) Behandlung von tieren mit il-2, zubereitungen dafuer und ihre herstellung.
DE3886517T2 (de) Menschlicher Prourokinase ähnliches Polypeptid.
NO871137D0 (no) Ikke-betennelsesfremkallende hyaluronsyrefraksjon og fremgangsmaate for fremstilling av denne.
NO880292D0 (no) Fremgangsmaate for behandling av humle.
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
NO872140D0 (no) Polyetere, fremstilling og anvendelse av slike.
NO874008D0 (no) Fremgangsmaate for behandling av fisk ved oppdeling, og anordning forutfoerelse av fremgangsmaaten.
NO885088D0 (no) Omslagsmateriale, fremgangsmŸte for dets fremstilling og fremgangsmŸte til bruk av materialet.
NO874617D0 (no) Fremgangsmaate til fremstilling av 2,6-diamino-3-halogenobenzylpyridiner.
NO884635D0 (no) Fremgangsmaate for behandling av most.
NO891986L (no) Fremgangsmaate for fremstilling av difenyl-sulfider, difenyl-sulfoksyder og difenylsulfoner.
NO883868L (no) Fremgangsmaate for diagnostisering av dsrna-mangeltilstander, samt fremgangsmaate for fremstilling av preparater for diagnostisering og behandling av slike tilstander.
NO880639D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive oksimetere av 2,6-dioksabicyklo (3, 3, 0)oktanoner.
DE3788424D1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).